CHU de Nice
Nice, France
NCT Number: NCT04361565
A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.
Looking for future studies?
Notify MeAll sexes
Observational
Nice, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Time frame: 45 days
Prevalence for anosmia in the COVID-19 + patients
Time frame: 45 days
Prevalence for ageusia in the COVID-19 + patients
Time frame: 45 days
Duration measured in days
Centre Hospitalier Universitaire de Nice
Other
Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04371510
COVID-19 by SARS-CoV-2 Infection
Nice, Alpes-Maritimes, France
View Trial DetailsNCT04385017
COVID-19 by SARS-CoV-2 Infection
Cannes, Alpes Maritimes, France
View Trial Details